犬用ワクチンの市場規模、シェア、動向分析レポート：ワクチンタイプ別、疾患タイプ別、投与経路別、免疫期間別、成分別、地域別、セグメント予測、2023年～2030年

犬用ワクチン市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の犬用ワクチンの市場規模は、2030年までに26億米ドルに達し、予測期間中のCAGRは6.0%になると予測されています。

この成長は、ペットの人間化、ミレニアル世代のペット飼育、予防ヘルスケアに関する意識の高まりといった動向に起因しています。Boehringer Ingelheim International GmbHによると、ミレニアル世代の35％、ベビーブーム世代の32％がペットを飼っています。さらに、ペットへの支出と保険の増加も、この市場の成長に拍車をかけると予想されています。WorldAnimalFoundation.orgが2023年2月に発表した記事によると、犬の飼い主は猫の飼い主よりも約570米ドル多く支出しています。

さらに、ペット人口の増加、中国やインドなどアジア太平洋の新興市場における所得水準の上昇、それに伴う人々のライフスタイルの変化は、犬用ワクチン産業の成長に大きな影響を与えると予想されます。例えば、Economic Timesが2023年7月に発表した記事によると、インドの一人当たり所得は1.6倍に増加し、2030年までには4,000米ドルに達すると予想されています。

犬用ワクチン市場レポートハイライト

• ワクチンタイプ別では、病気の予防と長期的な免疫の獲得に役立つことから、2022年には変性/弱毒化生ワクチン分野が52.4%の最大売上シェアを占めました。
• 疾患タイプ別では、犬狂犬病分野は、この疾患の高い有病率と人獣共通感染症の可能性により、予測期間中最も速いCAGR 6.9%で成長すると予測されます。
• 投与経路別では、注射剤は利便性が高く、正確な投与が可能であることから、2022年には76.1%と最大の売上シェアを占めました。
• 免疫期間別では、利便性の高さから1年投与型が2022年に51.2%のシェアを占めました。
• 成分別では、混合ワクチンが65.5%の最大シェアを占めています。複数の疾患を予防できることから、予測期間中のCAGRは6.2%と最速の成長が見込まれます。
• 北米は2022年に38.8%のシェアで支配的でしたが、これは大手企業の存在とペットの予防ヘルスケアに関する意識の高まりによるものです。一方、アジア太平洋地域は、中国とインドの新興経済国における未開拓のビジネスチャンスにより、予測期間中にCAGR 7.0%の急成長が見込まれています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 犬用ワクチン市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 普及と成長の見通しマッピング
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 犬用ワクチン市場分析ツール
  • 業界分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 犬用ワクチン：ワクチンタイプの推定・動向分析

• 犬用ワクチン市場：重要なポイント
• 犬用ワクチン市場：動向と市場シェア分析、2022年と2030年
• 変性/弱毒化生ワクチン
  • 変性/弱毒化生ワクチン市場推計・予測、2018年～2030年
• 不活性化（不活化）
  • 不活性化
• その他
  • その他の市場推計・予測、2018年～2030年

第5章 犬用ワクチン：疾患タイプの推定・動向分析

• 犬用ワクチン市場：重要なポイント
• 犬用ワクチン市場：動向と市場シェア分析、2022年と2030年
• 犬ジステンパー
  • 犬ジステンパー市場推計・予測、2018年～2030年
• 犬感染性呼吸器疾患複合体（CIRDC）
  • 犬感染性呼吸器疾患複合体
• 犬パルボウイルス症/パルボウイルス病
  • 犬パルボウイルス症/パルボウイルス病市場推計・予測、2018年～2030年
• 犬レプトスピラ症
  • 犬レプトスピラ症市場推計・予測、2018年～2030年
• 犬のライム病
  • 犬のライム病市場推計・予測、2018年～2030年
• 犬伝染性肝炎
  • 犬伝染性肝炎市場推計・予測、2018年～2030年
• 犬の狂犬病
  • 犬の狂犬病市場推計・予測、2018年～2030年
• その他の疾患
  • その他の疾患市場推計・予測、2018年～2030年

第6章 犬用ワクチン：投与経路の推定・動向分析

• 犬用ワクチン市場：重要なポイント
• 犬用ワクチン市場：動向と市場シェア分析、2022年と2030年
• 注射可能
  • 注射可能市場推計・予測、2018年～2030年
• 鼻腔内
  • 鼻腔内市場推計・予測、2018年～2030年
• 経口
  • 経口市場推計・予測、2018年～2030年

第7章 犬用ワクチン：免疫推定・動向分析

• 犬用ワクチン市場：重要なポイント
• 犬用ワクチン市場：動向と市場シェア分析、2022年と2030年
• 1年
  • 1年の市場推計・予測、2018年～2030年
• 3年
  • 3年の市場推計・予測、2018年～2030年
• その他
  • その他の市場推計・予測、2018年～2030年

第8章 犬用ワクチン：成分の推定・動向分析

• 犬用ワクチン市場：重要なポイント
• 犬用ワクチン市場：動向と市場シェア分析、2022年と2030年
• 混合ワクチン
  • 混合ワクチン市場推計・予測、2018年～2030年
• 単一ワクチン
  • 単一ワクチン市場推計・予測、2018年～2030年

第9章 犬用ワクチン市場：地域推定・動向分析

• 地域別の見通し
• 地域別の犬用ワクチン市場：重要なポイント
• 北米
  • 市場推計・予測、2018年～2030年
  • 米国
  • カナダ
• 欧州
  • 市場推計・予測、2018年～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 市場参入企業の分類
  • Bioveta, a.s.
  • HESTER BIOSCIENCES LIMITED
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma
  • Heska Corporation
  • Merck & Co., Inc.
  • Virbac
  • Zendal group
  • Elanco
  • Zoetis Services LLC

List of Tables

• 1. List of abbreviations
• 2. North America dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 3. North America dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 4. North America dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 5. North America dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 6. North America dog vaccine market, by component, 2018 - 2030 (USD Million)
• 7. North America dog vaccine market, by region, 2018 - 2030 (USD Million)
• 8. U.S. dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 9. U.S. dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 10. U.S. dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 11. U.S. dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 12. U.S. dog vaccine market, by component, 2018 - 2030 (USD Million)
• 13. Canada dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 14. Canada dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 15. Canada dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 16. Canada dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 17. Canada dog vaccine market, by component, 2018 - 2030 (USD Million)
• 18. Europe dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 19. Europe dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 20. Europe dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 21. Europe dog vaccine market, by duration of immunity type, 2018 - 2030 (USD Million)
• 22. Europe dog vaccine market, by component type, 2018 - 2030 (USD Million)
• 23. Europe dog vaccine market, by region, 2018 - 2030 (USD Million)
• 24. UK dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 25. UK dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 26. UK dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 27. UK dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 28. UK dog vaccine market, by component, 2018 - 2030 (USD Million)
• 29. Germany dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 30. Germany dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 31. Germany dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 32. Germany dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 33. Germany Dog Vaccine market, by component, 2018 - 2030 (USD Million)
• 34. France dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 35. France dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 36. France dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 37. France dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 38. Italy dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 39. Italy dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 40. Italy dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 41. Italy dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 42. Italy dog vaccine market, by component, 2018 - 2030 (USD Million)
• 43. Spain dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 44. Spain dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 45. Spain dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 46. Spain dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 47. Spain dog vaccine market, by component, 2018 - 2030 (USD Million)
• 48. Sweden dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 49. Sweden dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 50. Sweden dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 51. Sweden dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 52. Sweden dog vaccine market, by component, 2018 - 2030 (USD Million)
• 53. Norway dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 54. Norway dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 55. Norway dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 56. Norway pain dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 57. Norway dog vaccine market, by component, 2018 - 2030 (USD Million)
• 58. Denmark dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 59. Denmark dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 60. Denmark dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 61. Denmark dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 62. Denmark dog vaccine market, by component, 2018 - 2030 (USD Million)
• 63. Asia-Pacific dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 64. Asia-Pacific dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 65. Asia-Pacific dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 66. Asia-Pacific dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 67. Asia-Pacific dog vaccine market, by component, 2018 - 2030 (USD Million)
• 68. Asia pacific dog vaccine market, by region, 2018 - 2030 (USD Million)
• 69. Japan dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 70. Japan dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 71. Japan dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 72. Japan dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 73. Japan dog vaccine market, by component, 2018 - 2030 (USD Million)
• 74. China dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 75. China dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 76. China dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 77. China dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 78. China dog vaccine market, by component, 2018 - 2030 (USD Million)
• 79. India dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 80. India dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 81. India dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 82. India dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 83. India dog vaccine market, by component, 2018 - 2030 (USD Million)
• 84. Australia dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 85. Australia dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 86. Australia dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 87. Australia dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 88. Australia dog vaccine market, by component, 2018 - 2030 (USD Million)
• 89. Thailand dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 90. Thailand dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 91. Thailand dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 92. Thailand dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 93. Thailand dog vaccine market, by component, 2018 - 2030 (USD Million)
• 94. South Korea dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 95. South Korea dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 96. South Korea dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 97. South Korea dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 98. South Korea dog vaccine market, by component, 2018 - 2030 (USD Million)
• 99. Latin America dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 100. Latin America dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 101. Latin America dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 102. Latin America dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 103. Latin America dog vaccine market, by component, 2018 - 2030 (USD Million)
• 104. Latin America Dog Vaccine market, by region, 2018 - 2030 (USD Million)
• 105. Brazil dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 106. Brazil dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 107. Brazil dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 108. Brazil dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 109. Brazil dog vaccine market, by component, 2018 - 2030 (USD Million)
• 110. Mexico dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 111. Mexico dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 112. Mexico dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 113. Mexico dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 114. Mexico dog vaccine market, by component, 2018 - 2030 (USD Million)
• 115. Argentina dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 116. Argentina dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 117. Argentina dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 118. Argentina dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 119. Argentina dog vaccine market, by component, 2018 - 2030 (USD Million)
• 120. Middle East and Africa dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 121. Middle East and Africa dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 122. Middle East and Africa dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 123. Middle East and Africa dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 124. Middle East and Africa dog vaccine market, by component, 2018 - 2030 (USD Million)
• 125. Middle East and Africa Dog Vaccine market, by region, 2018 - 2030 (USD Million)
• 126. South Africa dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 127. South Africa dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 128. South Africa dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 129. South Africa dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 130. South Africa dog vaccine market, by component, 2018 - 2030 (USD Million)
• 131. Saudi Arabia dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 132. Saudi Arabia dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 133. Saudi Arabia dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 134. Saudi Arabia dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 135. Saudi Arabia dog vaccine market, by component, 2018 - 2030 (USD Million)
• 136. UAE dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 137. UAE dog vaccine market, by disease type, 2018 - 2030 (USD Million)
• 138. UAE dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 139. UAE dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 140. UAE dog vaccine market, by component, 2018 - 2030 (USD Million)
• 141. Kuwait dog vaccine market, by vaccine type, 2018 - 2030 (USD Million)
• 142. Kuwait dog vaccine market, by disease type, 2018 - 2030 (USD Million)]
• 143. Kuwait dog vaccine market, by route of administration, 2018 - 2030 (USD Million)
• 144. Kuwait dog vaccine market, by duration of immunity, 2018 - 2030 (USD Million)
• 145. Kuwait dog vaccine market, by component, 2018 - 2030 (USD Million)

List of Figure

1. Market research process

2. Data triangulation techniques

3. Primary research pattern

4. Market research approaches

5. QFD modeling for market share assessment

6. Market formulation & validation

7. Dog Vaccines: Market outlook

8. Dog Vaccines: Competitive insights

9. Parent market outlook

10. Related/ancillary market outlook

11. Penetration and growth prospect mapping

12. Industry value chain analysis

13. Dog vaccine market driver impact

14. Dog vaccine market restraint impact

15. Dog vaccine market strategic initiatives analysis

16. Dog vaccine market: Vaccine type movement analysis

17. Dog vaccine market: Vaccine type outlook and key takeaways

18. Modified/ attenuated live market estimates and forecasts, 2018 - 2030

19. Inactivated (Killed) market estimates and forecasts, 2018 - 2030

20. Others market estimates and forecasts, 2018 - 2030

21. Dog vaccine market: Disease type movement analysis

22. Dog vaccine market: Disease type outlook and key takeaways

23. Canine distemper market estimates and forecasts, 2018 - 2030

24. Canine infectious respiratory disease complex (CIRDC)market estimates and forecasts, 2018 - 2030

25. Canine parvovirosis/ parvovirus disease market estimates and forecasts, 2018 - 2030

26. Canine Lyme disease market estimates and forecasts, 2018 - 2030

27. Infectious canine hepatitis market estimates and forecasts, 2018 - 2030

28. Canine rabies market estimates and forecasts, 2018 - 2030

29. Other diseases market estimates and forecasts, 2018 - 2030

30. Dog Vaccine market: Route of administration movement analysis

31. Dog Vaccine market: Route of administration outlook and key takeaways

32. Injectable market estimates and forecasts, 2018 - 2030

33. Intranasal market estimates and forecasts, 2018 - 2030

34. Oral market estimates and forecasts, 2018 - 2030

35. Dog Vaccine market: Duration of immunity movement analysis

36. Dog Vaccine market: Duration of immunity outlook and key takeaways

37. 1 year market estimates and forecasts, 2018 - 2030

38. 3-year market estimates and forecasts, 2018 - 2030

39. others market estimates and forecasts, 2018 - 2030

40. Dog Vaccine market: Component movement analysis

41. Dog Vaccine market: Component of immunity outlook and key takeaways

42. Combined vaccines market estimates and forecasts, 2018 - 2030

43. Mono vaccines market estimates and forecasts, 2018 - 2030

44. Global dog vaccine market: Regional movement analysis

45. Global dog vaccine market: Regional outlook and key takeaways

46. North America market estimates and forecasts, 2018 - 2030

47. U.S. market estimates and forecasts, 2018 - 2030

48. Canada market estimates and forecasts, 2018 - 2030

49. Europe market estimates and forecasts, 2018 - 2030

50. UK market estimates and forecasts, 2018 - 2030

51. Germany market estimates and forecasts, 2018 - 2030

52. France market estimates and forecasts, 2018 - 2030

53. Italy market estimates and forecasts, 2018 - 2030

54. Spain market estimates and forecasts, 2018 - 2030

55. Denmark market estimates and forecasts, 2018 - 2030

56. Sweden market estimates and forecasts, 2018 - 2030

57. Norway market estimates and forecasts, 2018 - 2030

58. Asia Pacific market estimates and forecasts, 2018 - 2030

59. Japan market estimates and forecasts, 2018 - 2030

60. China market estimates and forecasts, 2018 - 2030

61. India market estimates and forecasts, 2018 - 2030

62. Australia market estimates and forecasts, 2018 - 2030

63. Thailand market estimates and forecasts, 2018 - 2030

64. South Korea market estimates and forecasts, 2018 - 2030

65. Latin America market estimates and forecasts, 2018 - 2030

66. Brazil market estimates and forecasts, 2018 - 2030

67. Mexico market estimates and forecasts, 2018 - 2030

68. Argentina market estimates and forecasts, 2018 - 2030

69. Middle East and Africa. market estimates and forecasts, 2018 - 2030

70. Saudi Arabia market estimates and forecasts, 2018 - 2030

71. South Africa market estimates and forecasts, 2018 - 2030

72. UAE market estimates and forecasts, 2018 - 2030

73. Kuwait market estimates and forecasts, 2018 - 2030

Dog Vaccine Market Growth & Trends:

The global dog vaccine market size is anticipated to reach USD 2.6 billion by 2030 and display a CAGR of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. The growth can be attributed to the increasing trend of pet humanization, pet ownership among millennials, and rising consciousness regarding preventive healthcare. According to Boehringer Ingelheim International GmbH, 35% of millennials and 32% of baby boomers own a pet. In addition, the rise in pet spending and insurance is also expected to add to the growth of this market. According to an article published by WorldAnimalFoundation.org in February 2023, dog owners spent approximately USD 570 more than cat owners.

Moreover, the increasing pet population, rising income levels in emerging markets of Asia-Pacific, such as China and India, and consequent changes in the lifestyle of people are expected to impact the growth of the dog vaccine industry significantly. For instance, according to an article published by the Economic Times in July 2023, the per capita income in India is expected to increase by 1.6 times to reach USD 4000 by 2030.

Dog Vaccine Market Report Highlights:

• Based on vaccine type, the modified/attenuated live vaccine segment accounted for the largest revenue share of 52.4% in 2022, as they help prevent disease and provide long-term immunity
• Based on disease type, the canine rabies segment is expected to grow at the fastest CAGR of 6.9% over the forecast period due to the high prevalence of this disease and its zoonotic potential
• Based on route of administration, the injectable segment accounted for the largest revenue share of 76.1% in 2022, owing to their convenience and ability to administer accurate dosage amounts
• Based on duration of immunity, the 1-year segment dominated the market with a share of 51.2% in 2022 owing to their convenience
• Based on component, the combined vaccines segment accounted for the largest market share of 65.5%. It is expected to grow at the fastest CAGR of 6.2% over the forecast period due to its ability to protect against more than one disease
• North America dominated with a share of 38.8% in 2022, owing to the presence of major players and increasing awareness regarding preventive healthcare for pets. On the other hand, Asia Pacific is anticipated to grow at the fastest CAGR of 7.0% over the forecast period due to untapped opportunities in the emerging economies of China and India

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Vaccine type
  • 1.1.2. Disease type
  • 1.1.3. Route of administration
  • 1.1.4. Duration of immunity
  • 1.1.5. Component
  • 1.1.6. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Vaccine type outlook
  • 2.2.2. Disease type outlook
  • 2.2.3. Route of administration outlook
  • 2.2.4. Duration of immunity outlook
  • 2.2.5. Component outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Dog Vaccine Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. Dog Vaccine Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Dog Vaccine: Vaccine Type Estimates & Trend Analysis

• 4.1. Dog Vaccine Market: Key Takeaways
• 4.2. Dog Vaccine Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Modified/Attenuated Live
  • 4.3.1. Modified/ attenuated live market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Inactivated (Killed)
  • 4.4.1. Inactivated (Killed) market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Others
  • 4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Dog Vaccine: Disease Type Estimates & Trend Analysis

• 5.1. Dog Vaccine Market: Key Takeaways
• 5.2. Dog Vaccine Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Canine Distemper
  • 5.3.1. Canine distemper market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Canine Infectious Respiratory Disease Complex (CIRDC)
  • 5.4.1. Canine infectious respiratory disease complex (CIRDC) market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Canine Parvovirosis/ Parvovirus Disease
  • 5.5.1. Canine parvovirosis/ parvovirus disease market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Canine Leptospirosis
  • 5.6.1. Canine leptospirosis market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Canine Lyme Disease
  • 5.7.1. Canine lyme disease market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.8. Infectious Canine Hepatitis
  • 5.8.1. Infectious canine hepatitis market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.9. Canine Rabies
  • 5.9.1. Canine distemper market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.10. Other Diseases
  • 5.10.1. Other diseases market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Dog Vaccine: Route of Administration Estimates & Trend Analysis

• 6.1. Dog Vaccine Market: Key Takeaways
• 6.2. Dog Vaccine Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Injectable
  • 6.3.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Intranasal
  • 6.4.1. Intranasal market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Oral
  • 6.5.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Dog Vaccine: Duration of Immunity Estimates & Trend Analysis

• 7.1. Dog Vaccine Market: Key Takeaways
• 7.2. Dog Vaccine Market: Movement & Market Share Analysis, 2022 & 2030
• 7.3. 1 Year
  • 7.3.1. 1-year market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.4. 3 Year
  • 7.4.1. 3-year market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Others
  • 7.5.1. others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Dog Vaccine: Component Estimates & Trend Analysis

• 8.1. Dog Vaccine Market: Key Takeaways
• 8.2. Dog Vaccine Market: Movement & Market Share Analysis, 2022 & 2030
• 8.3. Combined Vaccines
  • 8.3.1. Combined vaccines market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.4. Mono Vaccines
  • 8.4.1. Mono vaccines market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Dog Vaccine Market: Regional Estimates & Trend Analysis

• 9.1. Regional Outlook
• 9.2. Dog Vaccine Market by Region: Key Takeaways
• 9.3. North America
  • 9.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework/reimbursement structure
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 9.4. Europe
  • 9.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4.2. UK
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4.3. Germany
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework/reimbursement structure
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework/reimbursement structure
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key country dynamics
    • 9.4.9.2. Regulatory framework/reimbursement structure
    • 9.4.9.3. Competitive scenario
    • 9.4.9.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.5.5. Thailand
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.5.6. South Korea
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.6.2. Mexico
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/reimbursement structure
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Market Participant Categorization
  • 10.2.1. Bioveta, a.s.
    • 10.2.1.1. Company overview
    • 10.2.1.2. Financial performance
    • 10.2.1.3. Product benchmarking
    • 10.2.1.4. Strategic initiatives
  • 10.2.2. HESTER BIOSCIENCES LIMITED
    • 10.2.2.1. Company overview
    • 10.2.2.2. Financial performance
    • 10.2.2.3. Product benchmarking
    • 10.2.2.4. Strategic initiatives
  • 10.2.3. Boehringer Ingelheim International GmbH
    • 10.2.3.1. Company overview
    • 10.2.3.2. Financial performance
    • 10.2.3.3. Product benchmarking
    • 10.2.3.4. Strategic initiatives
  • 10.2.4. Brilliant Bio Pharma
    • 10.2.4.1. Company overview
    • 10.2.4.2. Financial performance
    • 10.2.4.3. Product benchmarking
    • 10.2.4.4. Strategic initiatives
  • 10.2.5. Heska Corporation
    • 10.2.5.1. Company overview
    • 10.2.5.2. Financial performance
    • 10.2.5.3. Product benchmarking
    • 10.2.5.4. Strategic initiatives
  • 10.2.6. Merck & Co., Inc.
    • 10.2.6.1. Company overview
    • 10.2.6.2. Financial performance
    • 10.2.6.3. Product benchmarking
    • 10.2.6.4. Strategic initiatives
  • 10.2.7. Virbac
    • 10.2.7.1. Company overview
    • 10.2.7.2. Financial performance
    • 10.2.7.3. Product benchmarking
    • 10.2.7.4. Strategic initiatives
  • 10.2.8. Zendal group
    • 10.2.8.1. Company overview
    • 10.2.8.2. Financial performance
    • 10.2.8.3. Product benchmarking
    • 10.2.8.4. Strategic initiatives
  • 10.2.9. Elanco
    • 10.2.9.1. Company overview
    • 10.2.9.2. Financial performance
    • 10.2.9.3. Product benchmarking
    • 10.2.9.4. Strategic initiatives
  • 10.2.10. Zoetis Services LLC
    • 10.2.10.1. Company overview
    • 10.2.10.2. Financial performance
    • 10.2.10.3. Product benchmarking
    • 10.2.10.4. Strategic initiatives